In 2024, exports of medicinal and pharmaceutical products from the European Union (EU) saw an impressive increase of 13.5% compared to the previous year, reaching 313.4 billion euros. This growth starkly contrasts with the modest 0.5% increase in imports, totaling 119.7 billion euros. As a result, the trade surplus in this sector reached a historic record of 193.6 billion euros, underscoring the strength of the European pharmaceutical market.
Germany led exports outside the EU, reaching 67.9 billion euros. Ireland followed with 56.6 billion and Belgium with 41.4 billion, solidifying these countries as powerhouses in the production and shipment of pharmaceutical products. In terms of imports, Germany also topped the list with 23.0 billion euros, followed by Belgium with 21.3 billion and the Netherlands with 14.7 billion.
The main destination for EU exports was the United States, which absorbed 38.2% of the total, equivalent to 119.8 billion euros. Switzerland came in second with 16.4%, or 51.3 billion euros, while the United Kingdom ranked third with 5.8% and 18.2 billion euros. In terms of imports, the United States again stood out as the largest supplier, representing 38.3%, translating to 45.9 billion euros, followed by Switzerland and the United Kingdom with 32.6% and 7.3%, respectively.
This panorama not only highlights the robustness of the pharmaceutical sector in the European economy, but also emphasizes the strategic importance of trade relations between the EU and its external partners. The increasing trend in exports suggests that European medicinal and pharmaceutical products are gaining competitiveness and demand in the global market.
Referrer: MiMub in Spanish
